Decrementally cost-effective health technologies in non-inferiority studies: A systematic review by Meryl Darlington, Raffaele Scarica, Xyomara Chavez-Pacheco, Laeticia Blamplain Segar, Isabelle Durand-Zaleski, Isabelle Durand-Zaleski

Get full text

Prognostic models for short-term annual risk of severe complications and mortality in patients living with type 2 diabetes using a national medical claim database by Alexandre Vimont, Sophie Béliard, René Valéro, Henri Leleu, Isabelle Durand-Zaleski

Get full text

In-Hospital Economic Burden of Metastatic Renal Cell Carcinoma in France in the Era of Targeted Therapies: Analysis of the French National Hospital Database from 2008 to 2013. by Rana Maroun, Franck Maunoury, Laure Benjamin, Gaëlle Nachbaur, Isabelle Durand-Zaleski

Get full text

Deploying and assessing telemedicine in the Paris region: progress report by Isabelle Durand-Zaleski, Kevin Zarca, Nathanael Charrier, Laurent Treluyer, Christine Calinaud

Get full text

Deploying and assessing telemedicine in the Paris region: progress report by Isabelle Durand-Zaleski, Kevin Zarca, Nathanael Charrier, Laurent Treluyer, Christine Calinaud

Get full text

How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example by Julie Bulsei, Meryl Darlington, Isabelle Durand-Zaleski, Michel Azizi, The DENERHTN Study Group

Get full text

Impact of the switch from four to three intradermal rabies post-exposure prophylaxis sessions in patients bitten by dogs: A cost-consequence analysis from the patients' perspective by Alicia Le Bras, Kevin Zarca, Yiksing Peng, Malen Chan, Isabelle Durand-Zaleski

Get full text

Cost-effectiveness of point-of-care viscoelastic haemostatic assays in the management of bleeding during cardiac surgery: protocol for a prospective multicentre pragmatic study wit... by Bertrand Rozec, Isabelle Durand-Zaleski, Jean-Christophe Rigal, Elodie Boissier, Karim Lakhal

Get full text

Editorial: Pharmacoeconomics in the era of health technology assessment and outcomes research to prioritize resource use, innovation and investment by François R. Girardin, Karen Cohen, Matthias Schwenkglenks, Matthias Schwenkglenks, Isabelle Durand-Zaleski

Get full text

Prevalence and cost of sickle cell disease in France: real-world analysis using data from the Echantillon Généraliste des Bénéficiaires by Maud Beillat, Isabelle Durand-Zaleski, France Pirenne, Stève Bénard, Louis Chillotti, Frédéric Galacteros

Get full text

Lung CAncer SCreening in French women using low-dose CT and Artificial intelligence for DEtection: the CASCADE study protocol by Isabelle Durand-Zaleski, Hendy Abdoul, Marie Wislez, Marie-Pierre Revel, Guillaume chassagnon, Emma Canniff

Get full text

Tele-expertise for diagnosis of skin lesions is cost-effective in a prison setting: A retrospective cohort study of 450 patients. by Kevin Zarca, Nathanael Charrier, Emmanuel Mahé, Fabien Guibal, Béatrice Carton, François Moreau, Isabelle Durand-Zaleski

Get full text

Peer review of grant applications: criteria used and qualitative study of reviewer practices. by Hendy Abdoul, Christophe Perrey, Philippe Amiel, Florence Tubach, Serge Gottot, Isabelle Durand-Zaleski, Corinne Alberti

Get full text

Effectiveness and Medicoeconomic Evaluation of Home Monitoring of Patients With Mild COVID-19: Covidom Cohort Study by Luc Jaulmes, Youri Yordanov, Alexandre Descamps, Isabelle Durand-Zaleski, Aurélien Dinh, Patrick Jourdain, Agnès Dechartres

Get full text

Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data by Rana Maroun, Laura Mitrofan, Laure Benjamin, Gaelle Nachbaur, Franck Maunoury, Philippe Le Jeunne, Isabelle Durand-Zaleski

Get full text

The cost of illness and burden of suicide and suicide attempts in France by Laeticia Blampain Segar, Charles Laidi, Ophélia Godin, Philippe Courtet, Guillaume Vaiva, Marion Leboyer, Isabelle Durand-Zaleski

Get full text

Parkinson’s disease with early motor complications: predicting EQ-5D- 3L utilities from PDQ-39 data in the EARLYSTIM trial by Mehdi Zahra, Isabelle Durand-Zaleski, Michal Górecki, Silke Walleser Autiero, Gillian Barnett, W. M. Michael Schüpbach

Get full text

Cost and outcomes of the ultrasound screening program for birth defects over time: a population-based study in France by Babak Khoshnood, Jean-Marie Jouannic, Clément Ferrier, Ferdinand Dhombres, Hanitra Randrianaivo, Isabelle Perthus, Isabelle Durand-Zaleski

Get full text

Study protocol for FASTRAK: a randomised controlled trial evaluating the cost impact and effectiveness of FAST-MRI for HCC suRveillance in pAtients with high risK of liver cancer by Étienne Audureau, Isabelle Durand-Zaleski, Maxime Ronot, Pierre Nahon, Samia Baloul, Olivier Sutter, Pierre-André Natella

Get full text

How to collect non-medical data in a pediatric trial: diaries or interviews by Anaïs Le Jeannic, Hassani Maoulida, Sophie Guilmin-Crépon, Corinne Alberti, Nadia Tubiana-Rufi, Isabelle Durand-Zaleski

Get full text